Clinical Report: Erratum on Prognostic Indicators for Adult DLBCL

Background

Diffuse large B-cell lymphoma (DLBCL) is a prevalent form of non-Hodgkin lymphoma characterized by significant genetic and clinical heterogeneity. Accurate prognostic indicators are crucial for risk stratification and treatment planning in DLBCL, given the high rates of relapse and refractory disease despite standard therapies.

Data Highlights

No numerical or trial data is presented in the erratum.

Key Findings

• The original ethics approval number was incorrectly reported as 2019-EC-55.
• The corrected ethics approval number is KY2025214.

Clinical Implications

Accurate reporting of ethics approval numbers is vital for the integrity of clinical research. Clinicians should remain aware of updates and corrections in published studies to ensure they are referencing the most accurate information.

Conclusion

This erratum emphasizes the importance of accuracy in clinical research documentation, particularly regarding ethics approvals.

Related Resources & Content

1. BMC Cancer, 2026 -- Erratum: Development of Prognostic Indicators and a Nomogram for Adult Diffuse Large B-Cell Lymphoma in a Retrospective Cohort from a Single Center
2. European Radiology — Creation and assessment of a radiomics nomogram utilizing [18F]FDG PET/CT to forecast prognostic risks in patients with pretreatment diffuse large B cell lymphoma
3. Blood Cancer Journal — Erratum: Low absolute peripheral blood CD4+ T-cell count predicts poor prognosis in R-CHOP-treated patients with diffuse large B-cell lymphoma
4. Blood Cancer Journal — Correction: A streamlined two-variable prognostic scoring model for individuals with newly diagnosed Hodgkin Lymphoma
5. Blood Cancer Journal — Correction: High-dose chemotherapy with autologous transplantation may improve outcomes in diffuse large B-cell lymphoma patients exhibiting MYC/BCL2 co-expression
6. SEOM–GOTEL clinical guidelines on diffuse large B-cell lymphoma (update 2025) - PMC
7. Diffuse large B-cell lymphoma — Onkopedia
8. Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma | Journal of Clinical Oncology
9. Laboratory Prognostic Index (LAB-PI) in diffuse large B-cell lymphoma: a single blood analysis predicts outcomes as good as IPI, NCCN-IPI, and GELTAMO-IPI - PMC
10. https://bmccancer.biomedcentral.com/counter/pdf/10.1186/s12885-025-15149-x.pdf
11. Development and Validation of Prognostic Models for Treatment Response of Patients with B-Cell Lymphoma: Standard Statistical and Machine-Learning Approaches - PMC